Hemispherx Biopharma (HEB) Announces Financial Results for the Three Months Ended March 31, 2013
5/9/2013 10:20:20 AM
More...
|
Hemispherx Biopharma (HEB) Gains Broad Treatment Expansion for Alferon N Injection® in Argentina
3/4/2013 11:33:59 AM
More...
|
Hemispherx Biopharma (HEB) Says FDA Rejects Fatigue Drug Application
2/5/2013 8:15:53 AM
More...
|
Robbins Arroyo LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against Hemispherx Biopharma (HEB)
1/18/2013 8:59:43 AM
More...
|
Hemispherx Biopharma (HEB) Announces Financial Results for the Three Months Ended September 30, 2012
11/5/2012 9:38:05 AM
More...
|
Hemispherx Biopharma (HEB) Announces FDA Confirms Advisory Committee Meeting on December 20, 2012
10/22/2012 9:14:33 AM
More...
|
Hemispherx Biopharma (HEB) Files for Treatment Expansion in Argentina for Alferon N Injection® for Hepatitis C
10/1/2012 9:55:24 AM
More...
|
Hemispherx Biopharma (HEB)'s Ampligen Rehash Unlikely to Impress FDA
9/27/2012 8:00:02 AM
More...
|
Hemispherx Biopharma (HEB) Announces FDA Advisory Committee Will Review Ampligen® for Chronic Fatigue Syndrome
9/24/2012 9:30:00 AM
More...
|
Hemispherx Biopharma (HEB) Reports on Annual Stockholder Meeting
9/20/2012 10:04:23 AM
More...
|
|